TGA Medical Device Classification for Taiwan Exporters: Classes and Pathways

The Therapeutic Goods Administration (TGA) classifies medical devices under the Therapeutic Goods (Medical Devices) Regulations 2002 into four risk-based categories: Class I (lowest risk), Class IIa (low-medium risk), Class IIb (medium-high risk), and Class III (highest risk). Class I devices include tongue depressors, elastic bandages, and non-powered wheelchairs, with an ARTG inclusion fee of AUD 3,200 and a processing timeline of 20 business days. Class IIa devices include blood pressure monitors, hearing aids, and powered nebulizers, requiring third-party conformity assessment and ARTG fees of AUD 4,800 with processing of 40 to 60 business days. Class IIb covers devices like TENS units, infusion pumps, and intensive care monitors at AUD 8,500 in fees and 90 to 120 business day processing.

Class III devices represent the highest risk category and include implantable pacemakers, drug-eluting stents, and total joint replacement prostheses. ARTG inclusion fees for Class III devices range from AUD 12,000 to AUD 15,000, with processing timelines of 150 to 255 business days (approximately 6 to 12 months). Additionally, Active Implantable Medical Devices (AIMD) have a separate classification pathway with fees starting at AUD 14,000. In vitro diagnostic (IVD) medical devices follow a parallel classification system with four classes (Class 1 through Class 4), governed by separate regulations under the Therapeutic Goods (Medical Devices) Regulations 2002 Part 4A.

Taiwan manufacturers of consumer health devices such as digital thermometers, pulse oximeters, and blood glucose monitors typically fall into Class IIa or Class IIb depending on the measurement technology and intended use. The classification is determined by the TGA's classification rules (Schedule 2 of the Medical Devices Regulations), which consider factors such as duration of contact with the body (transient, short-term, or long-term), invasiveness, whether the device is active or passive, and the body system being measured or affected. Misclassification is the most common error made by first-time exporters and can result in application rejection with forfeiture of the full application fee.

Before submitting any ARTG inclusion application, Taiwan exporters should request a formal pre-submission meeting with the TGA's Device Safety Branch, which costs AUD 1,600 for a 90-minute meeting and provides definitive classification guidance. This investment is negligible compared to the cost of a rejected application. The TGA also offers a free online classification tool at tga.gov.au that walks manufacturers through the classification rules, though the output is advisory and not binding. LNH31 Global recommends combining both resources: use the online tool for initial self-assessment, then confirm with a pre-submission meeting before committing to the application.

Every medical device sold in Australia must be included in the Australian Register of Therapeutic Goods (ARTG) before it can be lawfully imported, supplied, or exported. The ARTG inclusion application must be submitted by an Australian sponsor, which is defined as a person or entity that is ordinarily resident in Australia, or a body corporate established in Australia. Taiwan manufacturers cannot directly hold ARTG registrations; they must either establish an Australian subsidiary (Proprietary Limited company with a registered Australian address, costing AUD 1,200 to AUD 3,000 to incorporate) or appoint an Australian-based authorized representative to act as sponsor.

The Australian sponsor bears full legal responsibility for the device's compliance with the Essential Principles, post-market surveillance, adverse event reporting, and recall coordination. Sponsor responsibilities include maintaining a complaint handling system (responding to consumer complaints within 48 hours), submitting annual ARTG charge payments (AUD 1,360 per included device per year), reporting adverse events to the TGA within 10 calendar days for serious events and 30 days for non-serious events, and ensuring continuous compliance with the conditions of ARTG inclusion. Failure to meet sponsor obligations can result in civil penalties of up to AUD 555,000 per contravention for individuals and AUD 2.775 million for corporations.

Selecting the right Australian sponsor is critical for Taiwan medical device exporters. Professional regulatory affairs companies such as Novatech International (Melbourne), SeerPharma (Sydney), and Regulatory Professionals (Brisbane) offer sponsor-as-a-service arrangements starting at AUD 8,000 to AUD 15,000 per year per device, plus additional fees for application preparation and regulatory submissions. These companies maintain the required quality management infrastructure, insurance coverage, and regulatory expertise to fulfill sponsor obligations. Alternatively, Australian distributors of medical devices such as Device Technologies, Stryker Australia, or ResMed may act as sponsor for products they agree to distribute, though this limits your control over marketing and pricing.

The ARTG application itself requires extensive documentation: a completed TGA eBS (electronic Business Services) application form, evidence of conformity assessment (CE certificate or equivalent from a TGA-recognized conformity assessment body), manufacturer's quality management system certificate (ISO 13485:2016 from an accredited body), device master file including design documentation and risk analysis, Australian labeling artwork, and instructions for use in English. Applications are submitted through the TGA's eBS portal, and the evaluation clock starts once the application is deemed valid (complete). Incomplete applications receive a deficiency notice, which pauses the evaluation clock and can extend timelines by 4 to 8 weeks.

Conformity assessment is the process by which the TGA verifies that a medical device conforms to the applicable Essential Principles of safety and performance listed in Schedule 1 of the Therapeutic Goods (Medical Devices) Regulations 2002. There are 14 Essential Principles covering chemical, physical, and biological properties; infection and microbial contamination; construction and environmental properties; devices with a measuring function; protection against radiation; devices connected to or equipped with an energy source; information to be provided with the device; and clinical evidence. Each Essential Principle must be addressed in a checklist format with specific evidence referenced for compliance.

For Class I devices, the manufacturer can self-certify conformity by signing a Declaration of Conformity and maintaining a technical file. Class IIa, IIb, and III devices require conformity assessment by a TGA-recognized conformity assessment body. The TGA recognizes EU Notified Bodies (approximately 50 bodies), the US FDA (for certain device types under the mutual recognition agreement), and its own designated Australian conformity assessment bodies. Taiwan manufacturers with existing CE marking from an EU Notified Body can leverage this certification for TGA purposes, significantly reducing the time and cost of Australian market entry. The CE certificate must be current, issued by a Notified Body that appears on the TGA's list, and cover the specific device model being registered.

Clinical evidence requirements vary by device classification and novelty. Class I and IIa devices with a substantial equivalence to existing devices on the market may rely on a literature review and published clinical data, typically costing AUD 5,000 to AUD 15,000 to prepare. Class IIb devices usually require a more extensive clinical evaluation report including a systematic literature review, post-market clinical follow-up plan, and potentially a clinical investigation with Australian ethics committee approval (adding 6 to 12 months and AUD 50,000 to AUD 200,000). Class III devices almost always require device-specific clinical investigation data, with costs ranging from AUD 200,000 to over AUD 1 million depending on the device type and patient population.

Taiwan manufacturers should begin the conformity assessment process 12 to 18 months before the target Australian launch date. The recommended sequence is: obtain ISO 13485:2016 certification (3 to 6 months if not already certified), complete the Essential Principles checklist with all supporting evidence (2 to 3 months), engage a conformity assessment body for audit (1 to 3 months for scheduling plus 2 to 4 weeks for the actual audit), receive the conformity assessment certificate (4 to 8 weeks after audit), and then submit the ARTG application. Engaging an Australian regulatory consultant at the beginning of this process (AUD 200 to AUD 350 per hour, budget AUD 15,000 to AUD 25,000 total) will prevent costly rework and application rejections.

The TGA's fee structure for medical devices is published annually in the Therapeutic Goods (Charges) Regulations and updated each July 1. The 2025-2026 fee schedule includes: ARTG inclusion application for Class I devices at AUD 3,200, Class IIa at AUD 4,800, Class IIb at AUD 8,500, Class III at AUD 12,000 to AUD 15,000, and AIMD at AUD 14,000. Annual ARTG charges are AUD 1,360 per device per year, payable in January. Conformity assessment body audit fees are separate from TGA fees and range from AUD 8,000 to AUD 25,000 depending on the device class and audit complexity. Pre-submission meetings cost AUD 1,600 per 90-minute session.

Processing timelines are measured in working days from the date the application is deemed valid. Class I devices: 20 working days (approximately 4 weeks). Class IIa: 40 to 60 working days (8 to 12 weeks). Class IIb: 90 to 120 working days (18 to 24 weeks). Class III: 150 to 255 working days (30 to 51 weeks). These timelines can extend significantly if the TGA issues a request for information (RFI) during evaluation, which occurs in approximately 65 percent of Class IIb and Class III applications. Each RFI pauses the evaluation clock, and applicants have 20 working days to respond before the application may be withdrawn.

Post-market surveillance obligations begin immediately upon ARTG inclusion and continue for the entire period the device is on the Australian market. Sponsors must implement a systematic post-market surveillance plan proportionate to the device risk class, including complaint handling procedures, trend analysis, periodic safety update reports (every 2 years for Class IIb and III), and post-market clinical follow-up studies where required. The TGA conducts random post-market compliance audits on approximately 5 percent of registered devices annually, with audit costs borne by the TGA but corrective action costs borne by the sponsor.

Adverse event reporting to the TGA is mandatory and time-bound. Events involving death or serious deterioration of health must be reported within 10 calendar days. Events involving near-miss incidents that could have led to death or serious deterioration must be reported within 30 calendar days. The TGA received approximately 8,200 medical device adverse event reports in 2025, leading to 47 product recalls and 12 sponsor compliance enforcement actions. Taiwan manufacturers should establish an adverse event reporting procedure with their Australian sponsor before product launch and ensure that end-user complaints are funneled to the sponsor within 24 hours of receipt for triage and regulatory assessment.